Passage Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports an event occurring on February 29, 2024. Passage Bio, Inc. is incorporated in Delaware and its common stock trades on Nasdaq under the symbol PASG.
Key Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material Change Versus Prior Disclosure
- On February 29, 2024, Nasdaq confirmed that Passage Bio had regained compliance with Nasdaq Listing Rule 5450(a)(1), the minimum $1.00 closing bid-price requirement.
- As of February 28, 2024, the stock had maintained a closing bid price of at least $1.00 for 10 consecutive business days and the Company satisfied all other applicable continued-listing criteria.
- The Nasdaq listing matter is now closed.
- Previously, on August 31, 2023, Nasdaq had notified the Company that its stock had traded below $1.00 for 30 consecutive business days, resulting in noncompliance with the minimum bid-price requirement.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance, operating outlook, management forecast, contingency, or unusual accounting item. The reported listing deficiency has been resolved, but future compliance with Nasdaq requirements remains an item investors may monitor.
Investor Verification Points
- Verify the Nasdaq confirmation and closure of the minimum bid-price deficiency.
- Review subsequent filings for continued Nasdaq listing compliance and any additional listing requirements.
- Consult the Company’s periodic reports for financial condition, liquidity, operating results, and clinical-development updates, which are not included in this 8-K.